1. A retrospective analysis of combined chemoradiotherapy for locally advanced esophageal carcinoma
Tumor 2008;28(11):972-975
Objective: To explore the clinical response and prognosis of patients with locally advanced esophageal carcinoma after being treated with combined chemoradiotherapy. Methods: Thirty-five patients with locally advanced esophageal carcinoma were treated with radiotherapy (total radiation dosage, 45.0-50.4 Gy) and chemotherapy (5-FU plus cisplatin). Clinical response and survival time were analyzed according to their clinicopathological features. Results: The response rate was significantly higher in the patients who had the opportunity of surgery after chemoradiotherapy than those without opportunity of surgery (83.33% vs 47.83%, P = 0.023). Survival analysis confirmed that short-term efficacy and clinical staging were the important factors for progression-free survival (PFS) of patients (P <0.01, P <0.05). The efficacy of chemoradiotherapy affected overall survival (OS) statistically. The median OS for the patients with complete and partial response, stable disease, and progressed disease were 18 months, 15 months, and 6 months, respectively (P = 0.003). Conclusion: Combined chemoradiotherapy is effective in the treatment of locally advanced esophageal carcinoma. The efficacy of chemoradiotherapy is an important prognostic factor for progression-free survival and overall survival of patients.
2.THE THERAPEUTIC EFFECT OF MONOCLONAL ANTI EGFR ANTIBODY LEADING CHEMOTHERAPY TO HUMAN TUMOR
Guyin LOU ; Mei GENG ; Jinsong JIANG ;
Cancer Research and Clinic 2001;0(02):-
Objective:To explore the therapeutic effect of monoclonal anti EGFR antibody leading chemotherapy to human tumors.Methods:To prepare immunoconjugate of chemotherapy drugs with anti EGFR antibody and apply to clinic,and to observe it′s therapeutic effect and side effect. Results: This conjugated method could relief clinic symptoms and reduce side effect of tissues and organs significantly.Conclusion:Conjugates of monoclonal therapy of anti EGFR antibody and drug attached chemotherapy is a new and effective way for treatment of human tumors, and it can reduce side effect of the drugs meanwhile.
4.Analysis on Government Health Investment Process in Shanxi:an example of central special funds
Yunxia ZHANG ; Mei LI ; Jing YUAN ; Xinli GENG
Chinese Health Economics 2013;(11):49-50
Objective: To find out existed problems in government health investment process, it needs to increase efficiency rate of government health investment’s special fund. Methods: Through making statistics on the efficiency rate of central special funds in Shanxi government health investment, and analysis on the appropriate process of financial department of all levels. Results: Central government special funds distribution interval is too long, efficiency rate is low. Conclusion: It needs to accelerate special fund distribution and to carry out financial management model from province to county and enhance financial supervision.
5.Upper Limb Movement Deficiency in Children with Autism and Related Factors
Mei WANG ; Di GENG ; Yanping YANG ; Wenyan WANG
Chinese Journal of Rehabilitation Theory and Practice 2016;22(2):207-211
Objective To explore the deficiency of upper limb movement in children with autism and its related factors. Methods 30 au-tism children aged 7-13 years old, and 30 healthy children aged 7-8 years from February to May, 2014 were enrolled. Their range of motion, comprehensive strength and cooperation, endurance, and muscular tension were tested. Results All the indexes of autism children lagged be-hind the healthy children (P<0.01), expect the muscular tension of the right upper limb (P>0.05). The endurance of boys was better than girls (P=0.020), and there was no difference in other aspects between them (P>0.05). The type of autism for more upper limb movement cor-related with obstruction of Jianjing acupoint (GB21) (r=0.515, P=0.013), and was significantly different with the type of less limb move-ment (χ2=8.533, P=0.003). Conclusion Compared with healthy children, the joint motion is relatively flexible, but lack of strength, and with poor persistence and unbalance development between left and right upper limbs. Motor rehabilitation should be conducted according to their movement features and the condition of meridian.
6.Studies on sLe~(a/x) and Hematogenous Metastasis of Cancer
Yun-Li PENG ; Jing LI ; Mei-Yu GENG ;
China Biotechnology 2006;0(06):-
The expression of sLea/x which correlates with conventional histopathologic parameters serves as a useful indicator for the prognosis of metastatic disease. The bindings between sLea/x and their common ligand E-selectin initiate hematogenous metastasis of cancer. Certain bioactive conformation is crucial for the interaction between sLea/x and their ligands. Thus, a new class of compounds that mimic the structures of sLea/x can potently inhibit not only their functional bindings to selectins, but also the metastasis of cancer. This review is mainly on the sLea/x molecular structure,biosynthesis,distribution, especially the relationship between sLea/x and hematogenous metastasis of cancer and the design of drugs that mimic the structures of sLea/x.
7.Malignancy with immune thrombocytopenia
Fenqin ZHANG ; Mei GENG ; Wenqi XI ; Al ET
China Oncology 2001;0(02):-
Purpose:To study whether immune factors are involved in the occurrence of immune thrombocytopenia in some malignancy. Methods:Platelet associated antibodies and immune function were examined in 30 cases of malignancy with thrombocytopenia in our hospital. Results:Platelet associated antibodies(pAIgG,pAIgA,pAIgM)increased significantly in 11 of 30 patients with malignancy,especially those with metastatic adenocarcinoma and in the middle or advanced stage. Bleeding is common in these patients. After being treated with corticosteroid, immunosuppressive drugs or immunoglobulin,the platelet count of the patients increased and the bleeding syndrome improved. Conclusions:Thrombocytopenia in malignancy is partly due to the abnormal immune reaction of the patients.
8.SCHWABE Company's patent portfolio of Ginkgo biloba preparation.
Wei LIU ; Xin-Min CHENG ; Dong-Mei GENG ; Wei TAN ; Wen-Jun ZOU
China Journal of Chinese Materia Medica 2014;39(17):3384-3388
SCHWABE Company in German is the first and largest manufacturer of Ginkgo biloba preparation. The company not only has leading technology in this field, but also protects its own market effectively through the high quality of patent drafting and exactly patent layout. Based on multi-angle analysis for patent portfolio of G. biloba preparation at application time, legal status, globally layout, Chinese layout, the article provides technical reference of research and development of G. biloba, also provides valuable experience of traditonal Chinese medicine patent portfolio layout for Chinese enterprises.
Drug Industry
;
economics
;
legislation & jurisprudence
;
trends
;
Ginkgo biloba
;
chemistry
;
Humans
;
Patents as Topic
;
legislation & jurisprudence
;
Phytotherapy
;
economics
;
trends
;
Plant Preparations
;
isolation & purification
;
Technology, Pharmaceutical
;
economics
;
trends
9.Effect of sulfated polymannuroguluronate on Tat induced proinflammatory cytokines release in THP-1 cells and its mechanism of action.
Bin HUI ; Mei-yu GENG ; Jing LI
Acta Pharmaceutica Sinica 2006;41(4):338-341
AIMTo investigate the effects of sulfated polymannuroguluronate (SPMG), a novel candidate anti-AIDS drug in Phase II clinical trial, on Tat-induced release of proinflammatory cytokines (i.e., TNFalpha, IL-1beta and IL-6) and its related mechanism.
METHODSThe effects of SPMG on Tat induced TNFalpha (4 h), IL-1beta and IL-6 (6 h) secretion in THP-1 cells were measured by ELISA. Western blotting analysis was used to study the effects of SPMG on Tat induced PKCzeta, PKCtheta and PKCsigma phosphorylation.
RESULTSSPMG (50 to 100 microg x mL(-1)) markedly suppressed TNFalpha, IL-1beta and IL-6 secretion in Tat activated THP-1 cells. In THP-1 cells the phosphorylation levels of PKCzeta, PKCtheta and PKCsigma significantly increased following Tat stimulation, and only PKCsigma phosphorylation levels was inhibited by SPMG (50 to 100 microg x mL(-1)).
CONCLUSIONSPMG suppresses the secretion of proinflammatory cytokines in THP-1 cells may be by inhibiting PKCsigma activation.
Cell Line, Tumor ; Gene Products, tat ; pharmacology ; Humans ; Interleukin-1beta ; secretion ; Interleukin-6 ; secretion ; Isoenzymes ; metabolism ; Phosphorylation ; Polysaccharides ; pharmacology ; Protein Kinase C ; metabolism ; Protein Kinase C-delta ; metabolism ; Protein Kinase C-theta ; Tumor Necrosis Factor-alpha ; secretion